A Phase 1 interventional study of Rivaroxaban 18mg Oral Tablet and Rivaroxaban 20 MG Oral Tablet in Embolism and Thrombosis, sponsored by Addpharma Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-109 compared with AD-1091 in healthy male subjects.
53 studies on the registry are indexed under Embolism and Thrombosis; 11 are open to participants now.
This study's enrollment of 38 is below the median of 252 across 28 interventional studies indexed under Embolism and Thrombosis.
Browse Embolism and Thrombosis studies →Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
First submitted after Addpharma Inc. became part of Yuhan Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
Drug: Rivaroxaban 18mg Oral Tablet · Drug: Rivaroxaban 20 MG Oral Tablet
Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
Drug: Rivaroxaban 18mg Oral Tablet · Drug: Rivaroxaban 20 MG Oral Tablet
AD-109 (Rivaroxaban 18mg) Oral Tablet
AD-1091 (Rivaroxaban 20mg) Oral Tablet
Peak Plasma Concentration (Cmax)
Cmax of Rivaroxaban
Time frame: pre-dose to 34 hours
Area Under the Curve in time plot (AUCt)
AUCt of Rivaroxaban
Time frame: pre-dose to 34 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Dec 2021, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban